The Searle Company Delivers Strong Quarterly Performance with 31% Increase in Profit
The Searle Company Limited has reported a strong financial performance for the first quarter ended September 30, 2026, with its consolidated earnings showing significant growth in revenue and profitability. The pharmaceutical company recorded a 31% increase in profit after tax, supported by higher sales, improved gross profit margins and better operational efficiencies.
According to the company’s quarterly financial report, consolidated revenue increased to Rs11.18 billion during the quarter, compared with Rs9.70 billion in the corresponding period last year, representing year-on-year growth of approximately 15.24%.
The company’s profit after tax reached Rs1.195 billion, up from Rs914.15 million in the same quarter of the previous year. This improvement highlights the group’s ability to strengthen its financial performance despite operating challenges and rising business costs.
Improved Gross Profit Margin Supports Earnings Growth
The Searle Group also achieved a notable improvement in its gross profit margin, which increased to 57.23%, compared with 54.08% in the corresponding period last year.
Gross profit rose to Rs6.40 billion from Rs5.24 billion, reflecting the positive impact of pricing adjustments, a favourable product mix and improved supply chain management.
Profit from operations increased by approximately 22% to Rs2.23 billion, compared with Rs1.82 billion in the same period last year. The improvement came despite higher distribution and administrative expenses, demonstrating stronger operating performance.
Earnings Per Share Improves to Rs1.95
The company’s earnings performance also translated into improved returns per share. Basic and diluted earnings per share increased to Rs1.95 for the quarter, compared with Rs1.54 in September 2025.
The increase in earnings per share reflects the company’s improved profitability and stronger consolidated financial results.
Strategic Focus on Manufacturing and Pharmaceutical Innovation
Looking ahead, The Searle Company is focused on sustaining its growth momentum throughout FY2027 while strengthening its position across the pharmaceutical value chain.
The company plans to enhance manufacturing capabilities, improve operational efficiency, strengthen quality systems and optimize the utilization of available resources.
Its specialized medicines portfolio and Searle Biopharma business are expected to provide further opportunities for growth, particularly in biological medicines and potential strategic partnerships.
The company also intends to expand its international presence by strengthening existing export markets and pursuing product registrations in new geographical regions. Improved regulatory capabilities, reliable supply chains and manufacturing standards will remain important elements of this strategy.
Exports and Operational Efficiency Remain Key Priorities
International markets continue to play an important role in the company’s diversification strategy. Strong export growth during the quarter provides additional opportunities to expand its presence beyond domestic markets.
Management also plans to maintain financial discipline, manage operating costs and improve working capital management while pursuing sustainable business expansion.
Outlook
The Searle Company’s September 2026 quarterly results indicate a positive start to FY2027, with higher consolidated revenue, improved gross margins and stronger profitability.
The 31% increase in quarterly profit highlights the benefits of improved operational performance and a favourable product mix. Going forward, the company’s ability to maintain earnings growth will depend on manufacturing efficiency, successful market expansion, product development and effective cost management.
With continued investment in specialized medicines, biological products and international markets, The Searle Company aims to strengthen its competitive position and create sustainable long-term value for shareholders.
